Results from this study were presented in part at the International Congress of the Transplant Society in Sydney, Australia, August 10–14, 2008.
Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial
Article first published online: 10 JAN 2012
© copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 12, Issue 3, pages 694–705, March 2012
How to Cite
Abdelmalek, M. F., Humar, A., Stickel, F., Andreone, P., Pascher, A., Barroso, E., Neff, G. W., Ranjan, D., Toselli, L. T., Gane, E. J., Scarola, J., Goldberg-Alberts, R., Maller, E. S., Lo, C.-M. and for the Sirolimus Liver Conversion Trial Study Group (2012), Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial. American Journal of Transplantation, 12: 694–705. doi: 10.1111/j.1600-6143.2011.03919.x
- Issue published online: 28 FEB 2012
- Article first published online: 10 JAN 2012
- Received 04 February 2011, revised 23 August 2011 and accepted for publication 30 August 2011
- 4Sirolimus immunotherapy results in reduced rates of acute rejection in de novo orthotopic liver transplant recipients [abstract 1294]. Am J Transplant 2002; 2: 464., , , Rapamune Liver Transplant Study Group
- 15High risk of proteinuria and lack of improvement of kidney function following sirolimus conversion in liver transplant recipients [abstract 1370]. Am J Transplant 2008; 8: 543., , , , .
- 16Adverse effects and poor tolerance of sirolimus (SIR) in liver transplant recipients [abstract 480]. Am J Transplant 2008; 2(Suppl 2): 307., , , , , .
- 18A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694–1702., , , et al.